- Research article
- Open Access
Structural and antimicrobial properties of human pre-elafin/trappin-2 and derived peptides against Pseudomonas aeruginosa
© Bellemare et al; licensee BioMed Central Ltd. 2010
- Received: 2 June 2010
- Accepted: 8 October 2010
- Published: 8 October 2010
Pre-elafin/trappin-2 is a human innate defense molecule initially described as a potent inhibitor of neutrophil elastase. The full-length protein as well as the N-terminal "cementoin" and C-terminal "elafin" domains were also shown to possess broad antimicrobial activity, namely against the opportunistic pathogen P. aeruginosa. The mode of action of these peptides has, however, yet to be fully elucidated. Both domains of pre-elafin/trappin-2 are polycationic, but only the structure of the elafin domain is currently known. The aim of the present study was to determine the secondary structures of the cementoin domain and to characterize the antibacterial properties of these peptides against P. aeruginosa.
We show here that the cementoin domain adopts an α-helical conformation both by circular dichroism and nuclear magnetic resonance analyses in the presence of membrane mimetics, a characteristic shared with a large number of linear polycationic antimicrobial peptides. However, pre-elafin/trappin-2 and its domains display only weak lytic properties, as assessed by scanning electron micrography, outer and inner membrane depolarization studies with P. aeruginosa and leakage of liposome-entrapped calcein. Confocal microscopy of fluorescein-labeled pre-elafin/trappin-2 suggests that this protein possesses the ability to translocate across membranes. This correlates with the finding that pre-elafin/trappin-2 and elafin bind to DNA in vitro and attenuate the expression of some P. aeruginosa virulence factors, namely the biofilm formation and the secretion of pyoverdine.
The N-terminal cementoin domain adopts α-helical secondary structures in a membrane mimetic environment, which is common in antimicrobial peptides. However, unlike numerous linear polycationic antimicrobial peptides, membrane disruption does not appear to be the main function of either cementoin, elafin or full-length pre-elafin/trappin-2 against P. aeruginosa. Our results rather suggest that pre-elafin/trappin-2 and elafin, but not cementoin, possess the ability to modulate the expression of some P.aeruginosa virulence factors, possibly through acting on intracellular targets.
- Virulence Factor
- Phosphatidyl Glycerol
Pseudomonas aeruginosa is a Gram-negative bacterium that rarely causes serious infections in healthy individuals. It is, however, the prevalent opportunist pathogen encountered in nosocomial infections and the major etiologic agent responsible for the morbidity, clinical deterioration and early mortality associated with patients suffering from cystic fibrosis (CF) [1–5]. A plethora of virulence factors expressed by P. aeruginosa is associated with acute and chronic infections . Perhaps the most dramatic change that characterizes P. aeruginosa chronic infections is the transformation from a non-mucoid to a mucoid phenotype . This is associated with an overproduction of alginate, which favors biofilm formation and an increased antibiotic resistance . Chronic pseudomonal infections are thought to be virtually impossible to eradicate and the current strategy in the management of CF patients, which become infected in their early childhood, is to prevent or retard progression to chronic infection by treating P. aeruginosa infections with conventional antibiotic therapy as soon as they appear [9, 10].
In this era of increased antibiotic resistance, the development of novel antimicrobial agents is urgently needed. In the past decade, gene-encoded short positively charged peptides, collectively known as antimicrobial peptides (AMP), have attracted much attention because of their broad antimicrobial activities and their potential use as therapeutics [11–18]. AMP are characterized by their short length (12-50 aa), polycationic (at least +2 net charge as Lys or Arg) and, usually, amphipathic characters. Among the nearly thousand identified peptides from various organisms, four classes can be distinguished based on their structures; (i) amphipathic α-helical, (ii) β-sheet structures; (iii) extended structures, and (iv) hairpin loop stabilized by a single disulfide bridge. A common feature ascribed to AMP is their ability to interact with the negatively charged bacterial membranes and polyanionic cell surface (lipopolysaccharide (LPS) of Gram-negative and lipoteichoic acid of Gram-positive bacteria). At their lethal concentrations in vitro, they generally disrupt membrane integrity and cause bacterial lysis. Some AMP, however, do not cause membrane disruption, but act on intracellular targets such as nucleic acids .
We are studying the human multifunctional innate defense molecule known as pre-elafin/trappin-2. This protein is composed of two domains, an N-terminal moiety of 38 aa known as cementoin based on its ability to be cross-linked to extracellular matrix proteins through the action of a transglutaminase and a C-terminal part of 57 aa, or elafin domain, that displays sequence similarity with whey acidic protein (WAP) . This latter domain is a potent and specific inhibitor of neutrophil elastase (NE) and myeloblastin, as well as pancreatic elastase [21, 22]. Its structure was determined both by X-ray crystallography in complex with pancreatic elastase and free in solution by nuclear magnetic resonance (NMR) spectroscopy [23, 24]. The salient structural feature of elafin is a β-sheet stabilized by three disulfide bridges along with an inhibitory loop connected to the central β-sheet by a fourth disulfide bridge. There is no structural information regarding the cementoin domain or the full-length pre-elafin molecule.
Apart from the well-known inhibitory and anti-inflammatory properties of pre-elafin/trappin-2, previous studies also established that the full-length molecule and each of its domains possess broad antimicrobial activity, namely against the bacteria P. aeruginosa and S. aureus, and the yeast C. albicans[25–28]. Furthermore, adenoviral overexpression of pre-elafin/trappin-2 in a mouse model of acute P.aeruginosa infection was shown to reduce the bacterial load and to facilitate clearance of the microorganism . Although it has been documented that the full-length molecule is more active than its constituent domains in vitro[25, 27, 28], the exact mechanism of action of each of these peptides against microbial infections is largely unknown. We recently reported that the variable sensitivity of P. aeruginosa strains to pre-elafin/trappin-2 could be partly explained by the specific inhibition of a peptidase secreted by some, but not all, strains by the elafin domain . However, both domains also display antimicrobial activity independent from the peptidase inhibitory function of elafin suggesting that the antimicrobial properties of these peptides are the sum of several unique attributes [27, 28].
In the present study we have determined the secondary structures of the cementoin peptide in the presence or absence of membrane mimetics. This peptide is essentially unstructured in aqueous solution but, like a large class of AMPs, adopts an α-helical conformation in the hydrophobic membrane environment. However, when compared with magainin-2, a typical α-helical AMP with potent lytic activity , the lytic properties of cementoin, elafin or pre-elafin/trappin-2 toward P. aeruginosa and artificial membranes are very weak. We have also tested the ability of pre-elafin/trappin-2 and its domains to interfere with the expression of known P. aeruginosa virulence factors and compared this activity to that of azithromycin, an antibiotic that perturbs cell to cell communication in P. aeruginosa and significantly retards biofilm formation [31, 32]. Pre-elafin/trappin-2 and elafin, but not cementoin, were found to reduce biofilm development and the secretion of pyoverdine and this correlated with the ability of these peptides to bind DNA in vitro and to accumulate within the bacterial cytosol. Rather than causing extensive cell lysis, our data thus suggest that pre-elafin/trappin-2 and elafin attenuate the expression of some P. aeruginosa virulence factors, possibly through acting on an intracellular target.
The cementoin domain of pre-elafin/trappin-2 adopts an α-helical conformation in the presence of membrane mimetics
Using NMR, such a formation of structure upon addition of TFE was also apparent from the more dispersed 1H chemical shifts observed in the presence of 50% TFE (data not shown). These conditions were thus chosen to determine the secondary structures of cementoin. A series of triple-resonance spectra were recorded in order to assign backbone chemical shifts (Fig. 1B). From the assigned backbone chemical shifts, it was possible to predict secondary structures using the SSP approach (see Methods). This yielded two predicted helices in cementoin (Fig. 1C), similar to that predicted by AGADIR (Fig. 1D). Atomic resolution on spin relaxation data (R1, R2, NOE; see additional file 1: Fig. S1 A) confirmed most of AGADIR predictions. Indeed, residues for which high flexibility is inferred (from reduced spectral density mapping of spin relaxation data, see Fig. S1 B & C) are those located right before helix 1 as proposed by AGADIR, and directly after helix 2. Additionally, R2 data with higher values within proposed α - helices, but also in the middle of the peptide would tend to indicate that this whole section of the peptide is in slow exchange. Hence, both proposed α-helices could be nucleating points where α - helical structures would start appearing, enabling the transient existence of a long α-helix spanning residues 10-31. Of course, this structure would be transient as the NOE values are quite low (~0.5) for this whole stretch.
Diffusion behavior of cementoin in H2O and bicelles.
DHPC: DMPC: DMPG (8:3:1)
DHPC: DMPC: DMPG (8:3:1) + cementoin
Binding of pre-elafin/trappin-2 peptides to P. aeruginosa or artificial membranes does not cause extensive membrane disruption
We also addressed the lytic properties of these peptides by measuring the release of calcein entrapped within PG-composed liposomes. A 15-min exposure of liposome-entrapped calcein with magainin 2 led to a 32% release of calcein relative to that measured for liposomes permeabilized with 1% Triton X-100. In contrast, no more than 5% of calcein was released by either cementoin, elafin or pre-elafin/trappin-2. We thus conclude that these peptides have very weak lytic activities. This explains our finding that no measurable MIC (minimal inhibitory concentration) could be measured even if high concentrations of peptides were tested (up to 128 μg/mL for pre-elafin/trappin-2 and elafin and up to 256 μg/mL for cementoin).
Fluorescein-labeled pre-elafin/trappin-2 incubated with P. aeruginosa accumulates within the cytosol and both elafin and pre-elafin/trappin-2 bind DNA in vitro
Pre-elafin/trappin-2 and elafin attenuate the expression of known P. aeruginosa virulence factors
Attenuation of P. aeruginosa virulence factors by pre-elafin/trappin-2, elafin and cementoin
% Las B
71 ± 2
83 ± 2
76 ± 2
70 ± 2
59 ± 2
75 ± 2
72 ± 2
57 ± 4
82 ± 2
87 ± 4
79 ± 3
86 ± 2
69 ± 1
73 ± 5
77 ± 2
69 ± 2
96 ± 2
96 ± 4
95 ± 1
94 ± 2
91 ± 1
88 ± 4
87 ± 2
87 ± 2
69 ± 2
85 ± 4
80 ± 3
62 ± 4
55 ± 2
76 ± 2
75 ± 3
44 ± 5
The aim of the present study was to determine the secondary structures of the N-terminal moiety of pre-elafin/trappin-2 (cementoin) and to investigate the mode of action of this peptide compared to elafin and pre-elafin/trappin-2 against P. aeruginosa. We have shown here by CD and NMR studies that the cementoin peptide is essentially unstructured in aqueous solution but adopts an α-helical conformation in the presence of a membrane mimetic (TFE). This characteristic is shared with the most important class of AMP, the linear polycationic peptides , which include the human LL-37 peptide . Whilst TFE is known to induce α-helical structures by favoring intra hydrogen bonding, it has been demonstrated for a large number of AMP that this propensity to adopt an α-helical conformation in TFE is also observed in the presence of artificial membranes that more closely mimic the physiological environment . Hence, the secondary structures determined for cementoin in the presence of TFE are likely to be physiologically relevant. Previous studies showed that cementoin binds to the lipid core of lipopolysachharide (LPS) [27, 38] as well as to artificial membranes, particularly the negatively charged membranes enriched in PG . We confirmed here these finding by demonstrating that the translational diffusion of cementoin in the presence of DMPG-containing bicelles is considerably slower than that of free cementoin. Furthermore, we estimated that under the conditions used (peptide:lipid millimolar ratio of 1:200), approximately 87% of the cementoin peptide was bound to bicelles.
As revealed by SEM, binding of cementoin to P. aeruginosa elicited obvious morphological changes such as wrinkling and blister formation on the cell surface and the presence of pore-like structures. This is reminiscent to that described earlier for the binding of pre-elafin/trappin-2 to P. aeruginosa by Baranger et al.. However, in our hands the morphological changes induced by pre-elafin/trappin-2 were not as severe as those reported earlier or to that observed in the present study with cementoin and elafin alone. The reason for this apparent discrepancy is not clear but could be due to a different peptide to bacteria ratio and/or to the actual fraction of mature elafin present in the two preparations of pre-elafin/trappin-2. It is generally assumed that the presence of pore-like structures is indicative of cell lysis. However, several lines of evidence suggest that the membrane disruption properties of cementoin, elafin and pre-elafin/trappin-2 are considerably weaker compared to that of the amphibian lytic AMP magainin 2. First, unlike that observed with pre-elafin and derived peptides, numerous ghost cells were visualized by SEM upon incubation of P. aeruginosa with magainin 2. Second, compared to this AMP, outer and inner membrane depolarization by pre-elafin/trappin-2, elafin and cementoin, as measured with the probes NPN and DiSC3, were significantly weaker. Third, the release of liposome-entrapped calcein by magainin 2 was six-fold greater than that measured with any of the pre-elafin/trappin-2 derived peptides. Finally, no MIC values could be determined for cementoin, elafin or pre-elafin/trappin-2 compared to a MIC of 8 μg/mL for magainin 2 against P. aeruginosa ATCC 27853 strain . We therefore tentatively conclude that membrane disruption per se may not be the main function of these peptides in vivo.
Historically, the lytic properties of a peptide were important criteria to classify it as an AMP. It is however becoming increasingly documented that several AMP possess other functions such as modulating the host response, through interacting with innate defense molecules, or modifying the microbial behavior by acting on intracellular targets [19, 40, 41]. In line with this notion, pre-elafin/trappin-2 was recently proposed to opsonize P. aeruginosa to facilitate its clearance by macrophage . In the present work, we provided evidence that pre-elafin/trappin-2 may also traverse membranes, presumably to act on intracellular targets. A potential target could be DNA as both elafin and pre-elafin/trappin-2 were shown to bind DNA in vitro and this correlated with their ability to attenuate the expression of some P. aeruginosa virulence factors (see below). Buforin II is perhaps the best-documented AMP that acts on an intracellular target, the nucleic acids [43, 44]. Investigation of the membrane translocation mechanism of buforin II led to the proposal that this peptide induces the formation of a toroidal pore similar to that described for magainin 2 . However, unlike magainin 2, the short lifetime of the pore enables translocation of the peptide without causing membrane permeabilization and leakage of the intracellular content. The weak membrane depolarization and calcein release observed with pre-elafin/trappin-2 and elafin suggest that these peptides might be similarly translocated across lipid bilayers without causing extensive cell lysis. However, we cannot exclude the possibility that like Gramicidin A the size of the pores, rather than their lifetime, explains the weak membrane depolarization and calcein release observed . Future investigations using solid-state NMR to further characterize the interaction between pre-elafin/trappin-2 peptides and model membranes are needed to confirm their translocation properties and the exact mechanism involved.
Azithromycin is not considered an effective antibiotic against P. aeruginosa due to its high MIC value (> 64 μg/mL; [31, 47]). Yet, at sublethal concentrations for P. aeruginosa, azithromycin was found to retard biofilm formation  and to reduce the production of alginate, pyocyanin and the secretion of elastase (lasB) [31, 36]. We confirmed here these previous data and showed that it also reduces secretion of the siderophore pyoverdine. Both pre-elafin/trappin-2 and elafin were found to similarly affect the expression of P. aeruginosa virulence factors, namely the biofilm formation and the secretion of pyoverdine. Because these peptides were previously found to reduce the plating efficiency (cfu) of P. aeruginosa following a 3 h incubation with the peptides in phosphate buffer [25, 27], it could be argued that the observed attenuation on the expression of virulence factors is indirect. However, we believe this is unlikely for three reasons. First, all phenotypes were tested following prolonged incubation periods (ranging from 24 to 26 h) with the peptides in PSB medium. Under these conditions, the A595 nm of the cultures at the end of the incubation were almost undistinguishable between samples incubated in the presence or absence of peptides. Second, all phenotypes were quantified taking into account the final A595 nm of the cultures. Finally, whereas the plating efficiency of P. aeruginosa following a 3 h incubation with the peptides in phosphate buffer varied considerably between different strains (i.e. ATCC 27853 vs ATCC 33348; [25, 27]), this was not found to be the case for the reduced biofilm formation and secretion of pyoverdine between these two strains (data not shown). In further support to the role of pre-elafin/trappin-2 in the attenuation of P. aeruginosa virulence factors, it was recently reported that the A549 cell line expressing pre-elafin/trappin-2 reduces both the number of bacteria and the area of growing P. aeruginosa biofilm by approximately 50% . Although the effect of pre-elafin/trappin-2 and elafin is modest in vitro, this may contribute in vivo, along with the anti-inflammatory properties of these molecules, to prevent against P. aeruginosa infections.
We have demonstrated that the N-terminal moiety of pre-elafin/trappin-2 (cementoin) adopts an α-helical conformation in the presence of a membrane mimetic, which is typical of a large class of AMP. Despite the morphological changes observed at the surface of P. aeruginosa in the presence of cementoin, elafin or pre-elafin/trappin-2, the membrane disruption properties of these peptides are weak compared to magainin 2. We provided evidence that pre-elafin/trappin-2 and elafin may act on an intracellular target, possibly DNA. Although future studies on the interaction of these peptides with artificial membranes are needed to confirm and to elucidate the mechanism of membrane translocation, both pre-elafin/trappin-2 and elafin were shown to attenuate the expression of some P. aeruginosa virulence factors, which may contribute to the defense against P. aeruginosa infection.
Bacterial, yeast strains and growth conditions
P. aeruginosa strain ATCC #33348 was used in all functional assays with the pre-elafin/trappin- 2 and derived peptides. Bacteria were grown at 37°C with (250 rpm) or without agitation in peptone soy broth (PSB). E. coli strain BL21(DE3) (Novagen, Mississauga, ON, Canada) was used for the recombinant production of the cementoin peptide. The S. cerevisiae yeast strain YGAU-Ela2 (Matα his3 leu2 ura3 mf α1/mf α2Δ::LEU2 yps1Δ::HIS3 ura3::pGAU-Ela2) was used for the production of pre-elafin/trappin-2. This strain was constructed by integrating the plasmid pGAU-Ela2 (see below) digested by Nco I at the ura3 locus of the YBAD1 strain previously used for the production of pre-elafin/trappin-2 . Yeast cells were grown at 30°C in yeast dextrose peptone (YPD) medium.
Plasmids, oligonucleotides and DNA manipulations
DNA manipulations, bacterial and yeast transformations were all carried out according to standard procedures [50, 51]. Unless otherwise indicated, all restriction and DNA-modifying enzymes were purchased from New England Biolabs Ltd (Pickering, ON, Canada). The bacterial expression plasmid pET32-cem has been described previously for the production of the cementoin domain . The yeast integration plasmid pGAU-Ela2 was constructed by first excising the 2 μ origin of pVT-Ela2 through digestion with Bst X1 and Sma I, fill-in with the Klenow fragment and ligation. Next, the GAL1 promoter obtained as an Eco RI-Bam HI fragment from plasmid pJK6  was blunt-ended with Klenow and inserted into the unique Pvu II site located upstream of the pre-elafin fusion protein in pVT-Ela2 . The resulting integration plasmid was named pGAU-Ela2. All DNA constructs were verified for integrity by DNA sequencing.
Production and purification of recombinant pre-elafin and cementoin
Growth conditions for the production of bacterially expressed cementoin peptide were as described previously . For the production of pre-elafin/trappin-2, the yeast YGAU-Ela2 strain was first cultured 2 days at 30°C in 3 L of YPD with daily adjustments of the pH (pH 6.0) and addition of dextrose (1% w/v). The culture medium was then replaced by 1 L of synthetic complete -uracil medium supplemented with galactose 2% and the culture was resumed for another 2 days at 30°C with twice daily adjustments of the pH and additions of yeast nitrogen base (1% w/v) and galactose (1% w/v). Uniformly 15N-13C-labeled cementoin samples for NMR spectroscopy were prepared using 15NH4Cl and [13C]-glucose (Cambridge Isotope Laboratories, Andover, MA) as the sole nitrogen and carbon sources, as previously described . Induction with 1 mM isopropyl-β-D-thiogalactopyranoside (IPTG) was performed for 16 h at 37°C.
Purification of recombinant His-tagged pre-elafin/trappin-2 from yeast culture supernatants was essentially as described [49, 54], except the diafiltration proceeded in two steps. The permeate from a first diafiltration performed with the cleared supernatant over a 30-kDa cartridge was followed by concentration on a 3-kDa cartridge. Purification of the cementoin peptide from bacterial pellets, either uniformly labeled or not, was as previously described . Purified peptides were concentrated in deionized water using stirred-cells, lyophilized and stored at -80°C until use. Recombinant human elafin was purchased from AnaSpec (San Jose, CA, USA).
where MW is the peptide molecular weight (here 3948.54 g/mol), n is the number of residues in the peptide (here 38 residues), C is the peptide concentration (here 1g/L), and l is the length of the optical course (here 0.01 cm).
The AGADIR software http://agadir.crg.es/ developed by the Serrano's group [55–59] was used to predict the cementoin secondary structures. The parameters for ionic strength, temperature and pH were set to 1 M, 278°K and 7.0, respectively.
NMR samples were prepared by dissolving lyophilized protein in an aqueous solution at pH 6.4 to a final concentration of 0.5 mM and with 60 μM 2,2-dimethylsilapentane-5-sufonic acid and 10% D2O (for chemical shift referencing and locking, respectively). The spectra were recorded at a temperature of 2°C (calibrated with MeOH) on a 600 MHz Varian INOVA spectrometer equipped with either a room temperature triple resonance probe or a z-axis pulsed-field gradient triple resonance cold probe. Two-dimensional 15N-HSQC, 3D-HNCO, 3D-HN(CO)CA, and 3D-CBCA(CO)NH spectra (Biopack, Varian Inc., Palo Alto, CA) were recorded. NMR data were processed with NMRPipe/NMRDraw  and analyzed with NMRView . Backbone assignments proceeded within Smartnotebook v5.1.3 . The chemical shift index was calculated for both Cα and Cβ for secondary structure prediction using the SSP approach .
Where γ is 1H gyromagnetic ratio (2.6753 × 104 rad.s-1.G-1), δ is the duration of the pulse -field gradient (PFG, 0.4 s), G is the gradient strength (from 0.5 to 52 G.cm-1), Δ is the time between PFG trains (0.154 s) and Ds is the diffusion coefficient (in cm2.s-1).
where Dobs, Dfree and Dbound are the diffusion coefficients for all cementoin states (observed rate: 1.24 cm2.s-1), for free cementoin (4.28 cm2.s-1) and for bound cementoin (by approximation, for bicelles: 0.79 cm2.s-1), respectively, and pfree and pbound are the fractions for free and bound cementoin (with pfree + pbound = 1), respectively.
Backbone chemical shifts and spin relaxation data were deposited in the BMRB under accession number 16845.
Scanning electron micrography
Scanning electron micrography (SEM) of P. aeruginosa (~1 × 107 in 500 μL) incubated for 2 h in the absence or presence of the indicated peptides (8 μM) was performed on a JEOL JSM-6360LV microscope essentially as described , except samples were placed on Alcar© films and dehydrated by a series of incubation in alcohol (50, 70, 95 and 100%).
Outer and inner membrane depolarization of P. aeruginosa
The outer membrane depolarization activity of the recombinant peptides was determined by the 1-N-phenylnaphthylamine (NPN) uptake assay of Loh et al. with intact cells of P. aeruginosa using the Fluorescan Ascent FL microplate fluorometer. P. aeruginosa was grown with agitation to an A600 nm = 0.6 and harvested by centrifugation. The cells were washed in 5 mM HEPES, pH 7.8 and resuspended to an A600 nm of 0.5 in the same buffer. The microtiter plate wells were supplemented with cells (200 μL) and NPN dissolved in acetone was added to a final concentration of 10 μM. Then peptides were added to the desired concentration and the intensity of fluorescence was measured at λex = 355 nm and λem = 444 nm.
The cytoplasmic membrane depolarization activity of the peptides was determined as previously described with the membrane potential-sensitive dye DiSC3. Briefly, P. aeruginosa was grown at 37°C with agitation to an A600 nm of 0.6 and harvested by centrifugation. The cells were washed in 5 mM HEPES, pH 7.8 and resuspended to an A600 nm of 0.05 in the same buffer containing 20 mM glucose and 100 mM KCl. The cells were first treated with 15 mM EDTA pH 8.0 to permeabilize the outer membrane and allow the dye to reach the cytoplasmic membrane. Then, a stock solution of DiSC3 was added to a final concentration of 0.4 μM, and quenching was allowed to occur at room temperature. The desired concentration of peptides to be tested was added. Membrane depolarization was monitored with the Fluorescan Ascent FL microplate fluorometer by observing the change in the intensity of fluorescence (λex = 646 nm, λem = 678 nm) after the addition of the peptides.
Preparation of large unilamellar vesicles (liposomes) and leakage of calcein
Large unilamellar vesicles (liposomes) containing pure phosphatidylglycerol (PG) were prepared according to the previously described procedure . Liposome-entrapped calcein and removal of free calcein by Sephadex G-50 chromatography were carried out essentially as described .
For the calcein release assay, 10 μL of liposome suspension were diluted in 10 mM Tris-HCl pH 7.4, 150 mM NaCl buffer (final vol of 100 μL) and incubated for 15 min at room temperature in the presence or absence (negative control) of the indicated peptides at 8 μM or in the presence of 1% Triton X-100 (positive control). The change in the intensity of fluorescence (λex = 485 nm, λem = 527 nm) was monitored with a Fluorescan Ascent FL microplate fluorometer.
Bacteria were grown at 37°C with agitation in PSB medium to mid-logarithmic phase. Then, the cells were harvested by centrifugation, washed three times with 10 mM sodium phosphate buffer, pH 7.4 and resuspended in the same buffer to an A600 = 0.1. Bacteria were incubated with fluorescein-labeled full-length pre-elafin/trappin-2, prepared as described previously , for 1 h at 37°C in the dark. After incubation, cells were washed three times with phosphate buffer, and bacterial cells were mounted on a glass slide and microscopic observations (400 × magnification) of serial 0.2 μm sections were done with a Zeiss LSM 310 confocal microscope. Images were taken with an Olympus DP20 camera. As a negative control, free fluorescein incubated with bacteria and washed under the same conditions gave no fluorescent signal (data not shown).
DNA binding assay
EMSA experiments were performed by mixing 100 ng of plasmid DNA (pRS426) with increasing amounts of recombinant peptides in 20 μl of binding buffer (5% glycerol, 10 mM Tris-HCl (pH 8.0), 1 mM EDTA, 1 mM DTT, 20 mM KCl and 5% (w/v) BSA). DNA samples with or without peptides were co-incubated at room temperature for 1 h prior to electrophoresis on a 1.0% agarose gel.
Virulence factors assays
To assay for biofilm formation of P. aeruginosa an overnight culture was used to inoculate (~106 cells/ml) peptone soy broth media in 96 wells plates (Falcon 353072) in the presence or absence of recombinant peptide. The peptides were resuspended in 10 mM phosphate buffer (pH 7.4). The plate was incubated at 30°C for 26 h without agitation. The amounts of biofilm were determined by the method described by Peeters et al. using the dye crystal violet. Alginate production of P. aeruginosa from a 24 h culture was assayed according to the procedure described by Pedersen et al.. The enzymatic assay for lasB, from the cleared supernatants of a 24 h P. aeruginosa culture, was performed with the Congo red method as described previously . The amounts of pyoverdine secreted by the bacteria were estimated by measuring the absorbance at 405 nm of the cleared culture supernatants from 24 h cultures of P. aeruginosa as described by Ambrosi et al..
We would like to thank Richard Janvier for his valuable expertise in scanning electron micrography and confocal microscopy and Steve Charette for critical reading of the manuscript. We also acknowledge the Fonds québécois de la recherche sur la nature et les technologies for a studentship to A.B., the Regroupement québécois 'PROTEO' for a fellowship to N.V. and the Fonds de la recherche en santé du Québec for a studentship to S.M. This work was supported by grants from the Natural Sciences and Engineering Research Council of Canada to S.M.G. and Y.B.
- Sadikot RT, Blackwell TS, Christman JW, Prince AS: Pathogen-host interactions in Pseudomonas aeruginosa pneumonia. Am J Respir Crit Care Med. 2005, 171 (11): 1209-1223. 10.1164/rccm.200408-1044SO.PubMed CentralView ArticlePubMedGoogle Scholar
- Erwin AL, VanDevanter DR: The Pseudomonas aeruginosa genome: how do we use it to develop strategies for the treatment of patients with cystic fibrosis and Pseudomonas infections?. Curr Opin Pulm Med. 2002, 8 (6): 547-551. 10.1097/00063198-200211000-00011.View ArticlePubMedGoogle Scholar
- Richards MJ, Edwards JR, Culver DH, Gaynes RP: Nosocomial infections in medical intensive care units in the United States. National Nosocomial Infections Surveillance System. Crit Care Med. 1999, 27 (5): 887-892. 10.1097/00003246-199905000-00020.View ArticlePubMedGoogle Scholar
- Elkin S, Geddes D: Pseudomonal infection in cystic fibrosis: the battle continues. Expert Rev Anti Infect Ther. 2003, 1 (4): 609-618. 10.1586/1478722.214.171.1249.View ArticlePubMedGoogle Scholar
- Zhang L, Parente J, Harris SM, Woods DE, Hancock RE, Falla TJ: Antimicrobial peptide therapeutics for cystic fibrosis. Antimicrob Agents Chemother. 2005, 49 (7): 2921-2927. 10.1128/AAC.49.7.2921-2927.2005.PubMed CentralView ArticlePubMedGoogle Scholar
- Kipnis E, Sawa T, Wiener-Kronish J: Targeting mechanisms of Pseudomonas aeruginosa pathogenesis. Med Mal Infect. 2006, 36 (2): 78-91. 10.1016/j.medmal.2005.10.007.View ArticlePubMedGoogle Scholar
- Murray TS, Egan M, Kazmierczak BI: Pseudomonas aeruginosa chronic colonization in cystic fibrosis patients. Curr Opin Pediatr. 2007, 19 (1): 83-88. 10.1097/MOP.0b013e3280123a5d.View ArticlePubMedGoogle Scholar
- Hentzer M, Teitzel GM, Balzer GJ, Heydorn A, Molin S, Givskov M, Parsek MR: Alginate overproduction affects Pseudomonas aeruginosa biofilm structure and function. J Bacteriol. 2001, 183 (18): 5395-5401. 10.1128/JB.183.18.5395-5401.2001.PubMed CentralView ArticlePubMedGoogle Scholar
- Doring G, Hoiby N: Early intervention and prevention of lung disease in cystic fibrosis: a European consensus. J Cyst Fibros. 2004, 3 (2): 67-91. 10.1016/j.jcf.2004.03.008.View ArticlePubMedGoogle Scholar
- Hoiby N, Frederiksen B, Pressler T: Eradication of early Pseudomonas aeruginosa infection. J Cyst Fibros. 2005, 4 (Suppl 2): 49-54. 10.1016/j.jcf.2005.05.018.View ArticlePubMedGoogle Scholar
- Hancock RE, Lehrer R: Cationic peptides: a new source of antibiotics. Trends Biotechnol. 1998, 16 (2): 82-88. 10.1016/S0167-7799(97)01156-6.View ArticlePubMedGoogle Scholar
- Schwab U, Gilligan P, Jaynes J, Henke D: In vitro activities of designed antimicrobial peptides against multidrug-resistant cystic fibrosis pathogens. Antimicrob Agents Chemother. 1999, 43 (6): 1435-1440.PubMed CentralPubMedGoogle Scholar
- Singh PK, Tack BF, McCray PB, Welsh MJ: Synergistic and additive killing by antimicrobial factors found in human airway surface liquid. Am J Physiol Lung Cell Mol Physiol. 2000, 279 (5): L799-805.PubMedGoogle Scholar
- Devine DA: Antimicrobial peptides in defence of the oral and respiratory tracts. Mol Immunol. 2003, 40 (7): 431-443. 10.1016/S0161-5890(03)00162-7.View ArticlePubMedGoogle Scholar
- Zhang L, Falla TJ: Cationic antimicrobial peptides - an update. Expert Opin Investig Drugs. 2004, 13 (2): 97-106. 10.1517/135437126.96.36.199.View ArticlePubMedGoogle Scholar
- Toke O: Antimicrobial peptides: new candidates in the fight against bacterial infections. Biopolymers. 2005, 80 (6): 717-735. 10.1002/bip.20286.View ArticlePubMedGoogle Scholar
- De Smet K, Contreras R: Human antimicrobial peptides: defensins, cathelicidins and histatins. Biotechnol Lett. 2005, 27 (18): 1337-1347. 10.1007/s10529-005-0936-5.View ArticlePubMedGoogle Scholar
- Zhang L, Falla TJ: Antimicrobial peptides: therapeutic potential. Expert Opin Pharmacother. 2006, 7 (6): 653-663. 10.1517/146565188.8.131.523.View ArticlePubMedGoogle Scholar
- Hale JD, Hancock RE: Alternative mechanisms of action of cationic antimicrobial peptides on bacteria. Expert Rev Anti Infect Ther. 2007, 5 (6): 951-959. 10.1586/14787184.108.40.2061.View ArticlePubMedGoogle Scholar
- Schalkwijk J, Wiedow O, Hirose S: The trappin gene family: proteins defined by an N-terminal transglutaminase substrate domain and a C-terminal four-disulphide core. Biochem J. 1999, 340 (Pt 3): 569-577. 10.1042/0264-6021:3400569.PubMed CentralView ArticlePubMedGoogle Scholar
- Wiedow O, Schroder JM, Gregory H, Young JA, Christophers E: Elafin: an elastase-specific inhibitor of human skin. Purification, characterization, and complete amino acid sequence. J Biol Chem. 1990, 265 (25): 14791-14795.PubMedGoogle Scholar
- Wiedow O, Luademann J, Utecht B: Elafin is a potent inhibitor of proteinase 3. Biochem Biophys Res Commun. 1991, 174 (1): 6-10. 10.1016/0006-291X(91)90476-N.View ArticlePubMedGoogle Scholar
- Tsunemi M, Matsuura Y, Sakakibara S, Katsube Y: Crystal structure of an elastase-specific inhibitor elafin complexed with porcine pancreatic elastase determined at 1.9 A resolution. Biochemistry. 1996, 35 (36): 11570-11576. 10.1021/bi960900l.View ArticlePubMedGoogle Scholar
- Francart C, Dauchez M, Alix AJ, Lippens G: Solution structure of R-elafin, a specific inhibitor of elastase. J Mol Biol. 1997, 268 (3): 666-677. 10.1006/jmbi.1997.0983.View ArticlePubMedGoogle Scholar
- Simpson AJ, Maxwell AI, Govan JR, Haslett C, Sallenave JM: Elafin (elastase-specific inhibitor) has anti-microbial activity against gram-positive and gram-negative respiratory pathogens. FEBS Lett. 1999, 452 (3): 309-313. 10.1016/S0014-5793(99)00670-5.View ArticlePubMedGoogle Scholar
- Meyer-Hoffert U, Wichmann N, Schwichtenberg L, White PC, Wiedow O: Supernatants of Pseudomonas aeruginosa induce the Pseudomonas-specific antibiotic elafin in human keratinocytes. Exp Dermatol. 2003, 12 (4): 418-425. 10.1034/j.1600-0625.2002.120409.x.View ArticlePubMedGoogle Scholar
- Bellemare A, Vernoux N, Morisset D, Bourbonnais Y: Human pre-elafin inhibits a Pseudomonas aeruginosa-secreted peptidase and prevents its proliferation in complex media. Antimicrob Agents Chemother. 2008, 52 (2): 483-490. 10.1128/AAC.00585-07.PubMed CentralView ArticlePubMedGoogle Scholar
- Baranger K, Zani ML, Chandenier J, Dallet-Choisy S, Moreau T: The antibacterial and antifungal properties of trappin-2 (pre-elafin) do not depend on its protease inhibitory function. FEBS J. 2008, 275 (9): 2008-2020. 10.1111/j.1742-4658.2008.06355.x.View ArticlePubMedGoogle Scholar
- Simpson AJ, Wallace WA, Marsden ME, Govan JR, Porteous DJ, Haslett C, Sallenave JM: Adenoviral augmentation of elafin protects the lung against acute injury mediated by activated neutrophils and bacterial infection. J Immunol. 2001, 167 (3): 1778-1786.View ArticlePubMedGoogle Scholar
- Matsuzaki K: Magainins as paradigm for the mode of action of pore forming polypeptides. Biochim Biophys Acta. 1998, 1376 (3): 391-400.View ArticlePubMedGoogle Scholar
- Hoffmann N, Lee B, Hentzer M, Rasmussen TB, Song Z, Johansen HK, Givskov M, Hoiby N: Azithromycin blocks quorum sensing and alginate polymer formation and increases the sensitivity to serum and stationary-growth-phase killing of Pseudomonas aeruginosa and attenuates chronic P. aeruginosa lung infection in Cftr(-/-) mice. Antimicrob Agents Chemother. 2007, 51 (10): 3677-3687. 10.1128/AAC.01011-06.PubMed CentralView ArticlePubMedGoogle Scholar
- Favre-Bonte S, Kohler T, Van Delden C: Biofilm formation by Pseudomonas aeruginosa: role of the C4-HSL cell-to-cell signal and inhibition by azithromycin. J Antimicrob Chemother. 2003, 52 (4): 598-604. 10.1093/jac/dkg397.View ArticlePubMedGoogle Scholar
- Haney EF, Hunter HN, Matsuzaki K, Vogel HJ: Solution NMR studies of amphibian antimicrobial peptides: linking structure to function?. Biochim Biophys Acta. 2009, 1788 (8): 1639-1655. 10.1016/j.bbamem.2009.01.002.View ArticlePubMedGoogle Scholar
- Loh B, Grant C, Hancock RE: Use of the fluorescent probe 1-N-phenylnaphthylamine to study the interactions of aminoglycoside antibiotics with the outer membrane of Pseudomonas aeruginosa. Antimicrob Agents Chemother. 1984, 26 (4): 546-551.PubMed CentralView ArticlePubMedGoogle Scholar
- Wu M, Hancock RE: Interaction of the cyclic antimicrobial cationic peptide bactenecin with the outer and cytoplasmic membrane. J Biol Chem. 1999, 274 (1): 29-35. 10.1074/jbc.274.1.29.View ArticlePubMedGoogle Scholar
- Nalca Y, Jansch L, Bredenbruch F, Geffers R, Buer J, Haussler S: Quorum-sensing antagonistic activities of azithromycin in Pseudomonas aeruginosa PAO1: a global approach. Antimicrob Agents Chemother. 2006, 50 (5): 1680-1688. 10.1128/AAC.50.5.1680-1688.2006.PubMed CentralView ArticlePubMedGoogle Scholar
- Li X, Li Y, Han H, Miller DW, Wang G: Solution structures of human LL-37 fragments and NMR-based identification of a minimal membrane-targeting antimicrobial and anticancer region. J Am Chem Soc. 2006, 128 (17): 5776-5785. 10.1021/ja0584875.View ArticlePubMedGoogle Scholar
- McMichael JW, Roghanian A, Jiang L, Ramage R, Sallenave JM: The antimicrobial antiproteinase elafin binds to lipopolysaccharide and modulates macrophage responses. Am J Respir Cell Mol Biol. 2005, 32 (5): 443-452. 10.1165/rcmb.2004-0250OC.View ArticlePubMedGoogle Scholar
- Giacometti A, Cirioni O, Barchiesi F, Fortuna M, Scalise G: In-vitro activity of cationic peptides alone and in combination with clinically used antimicrobial agents against Pseudomonas aeruginosa. J Antimicrob Chemother. 1999, 44 (5): 641-645. 10.1093/jac/44.5.641.View ArticlePubMedGoogle Scholar
- Brogden KA: Antimicrobial peptides: pore formers or metabolic inhibitors in bacteria?. Nat Rev Microbiol. 2005, 3 (3): 238-250. 10.1038/nrmicro1098.View ArticlePubMedGoogle Scholar
- Otvos L: Antibacterial peptides and proteins with multiple cellular targets. J Pept Sci. 2005, 11 (11): 697-706. 10.1002/psc.698.View ArticlePubMedGoogle Scholar
- Wilkinson TS, Dhaliwal K, Hamilton TW, Lipka AF, Farrell L, Davidson DJ, Duffin R, Morris AC, Haslett C, Govan JR, Gregory CD, Sallenave JM, Simpson AJ: Trappin-2 promotes early clearance of Pseudomonas aeruginosa through CD14-dependent macrophage activation and neutrophil recruitment. Am J Pathol. 2009, 174 (4): 1338-1346. 10.2353/ajpath.2009.080746.PubMed CentralView ArticlePubMedGoogle Scholar
- Park CB, Kim HS, Kim SC: Mechanism of action of the antimicrobial peptide buforin II: buforin II kills microorganisms by penetrating the cell membrane and inhibiting cellular functions. Biochem Biophys Res Commun. 1998, 244 (1): 253-257. 10.1006/bbrc.1998.8159.View ArticlePubMedGoogle Scholar
- Park CB, Yi KS, Matsuzaki K, Kim MS, Kim SC: Structure-activity analysis of buforin II, a histone H2A-derived antimicrobial peptide: the proline hinge is responsible for the cell-penetrating ability of buforin II. Proc Natl Acad Sci USA. 2000, 97 (15): 8245-8250. 10.1073/pnas.150518097.PubMed CentralView ArticlePubMedGoogle Scholar
- Kobayashi S, Chikushi A, Tougu S, Imura Y, Nishida M, Yano Y, Matsuzaki K: Membrane translocation mechanism of the antimicrobial peptide buforin 2. Biochemistry. 2004, 43 (49): 15610-15616. 10.1021/bi048206q.View ArticlePubMedGoogle Scholar
- Katsu T, Imamura T, Komagoe K, Masuda K, Mizushima T: Simultaneous measurements of K+ and calcein release from liposomes and the determination of pore size formed in a membrane. Anal Sci. 2007, 23 (5): 517-522. 10.2116/analsci.23.517.View ArticlePubMedGoogle Scholar
- Molinari G, Guzman CA, Pesce A, Schito GC: Inhibition of Pseudomonas aeruginosa virulence factors by subinhibitory concentrations of azithromycin and other macrolide antibiotics. J Antimicrob Chemother. 1993, 31 (5): 681-688. 10.1093/jac/31.5.681.View ArticlePubMedGoogle Scholar
- Li Q, Zhou X, Nie X, Yang J: The role of recombinant human elafin in the resistance of A549 cells against Pseudomonas aeruginosa biofilm. Respiration. 2010, 79 (1): 68-75. 10.1159/000218154.View ArticlePubMedGoogle Scholar
- Bourbonnais Y, Larouche C, Tremblay GM: Production of full-length human pre-elafin, an elastase specific inhibitor, from yeast requires the absence of a functional yapsin 1 (Yps1p) endoprotease. Protein Expr Purif. 2000, 20 (3): 485-491. 10.1006/prep.2000.1338.View ArticlePubMedGoogle Scholar
- Sambrook J, Fritsch EF, Maniatis T: Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory. 1989, New York: Cold Spring Harbor Laboratory PressGoogle Scholar
- Kaiser C, Michaelis S, Mitchell A: Laboratory Course Manual for Methods in Yeast Genetics, Cold Spring Harbor Laboratory. 1994, New York: Cold Spring Harbor Laboratory PressGoogle Scholar
- Bourbonnais Y, Ash J, Daigle M, Thomas DY: Isolation and characterization of S. cerevisiae mutants defective in somatostatin expression: cloning and functional role of a yeast gene encoding an aspartyl protease in precursor processing at monobasic cleavage sites. EMBO J. 1993, 12 (1): 285-294.PubMed CentralPubMedGoogle Scholar
- Doucet N, Savard PY, Pelletier JN, Gagne SM: NMR investigation of Tyr105 mutants in TEM-1 beta-lactamase: dynamics are correlated with function. J Biol Chem. 2007, 282 (29): 21448-21459. 10.1074/jbc.M609777200.View ArticlePubMedGoogle Scholar
- Doucet A, Bouchard D, Janelle MF, Bellemare A, Gagne S, Tremblay GM, Bourbonnais Y: Characterization of human pre-elafin mutants: full antipeptidase activity is essential to preserve lung tissue integrity in experimental emphysema. Biochem J. 2007, 405 (3): 455-463. 10.1042/BJ20070020.PubMed CentralView ArticlePubMedGoogle Scholar
- Munoz V, Serrano L: Elucidating the folding problem of helical peptides using empirical parameters. Nat Struct Biol. 1994, 1 (6): 399-409. 10.1038/nsb0694-399.View ArticlePubMedGoogle Scholar
- Munoz V, Serrano L: Elucidating the folding problem of helical peptides using empirical parameters. III. Temperature and pH dependence. J Mol Biol. 1995, 245 (3): 297-308. 10.1006/jmbi.1994.0024.View ArticlePubMedGoogle Scholar
- Munoz V, Serrano L: Elucidating the folding problem of helical peptides using empirical parameters. II. Helix macrodipole effects and rational modification of the helical content of natural peptides. J Mol Biol. 1995, 245 (3): 275-296. 10.1006/jmbi.1994.0023.View ArticlePubMedGoogle Scholar
- Munoz V, Serrano L: Development of the multiple sequence approximation within the AGADIR model of alpha-helix formation: comparison with Zimm-Bragg and Lifson-Roig formalisms. Biopolymers. 1997, 41 (5): 495-509. 10.1002/(SICI)1097-0282(19970415)41:5<495::AID-BIP2>3.0.CO;2-H.View ArticlePubMedGoogle Scholar
- Lacroix E, Viguera AR, Serrano L: Elucidating the folding problem of alpha-helices: local motifs, long-range electrostatics, ionic-strength dependence and prediction of NMR parameters. J Mol Biol. 1998, 284 (1): 173-191. 10.1006/jmbi.1998.2145.View ArticlePubMedGoogle Scholar
- Delaglio F, Grzesiek S, Vuister GW, Zhu G, Pfeifer J, Bax A: NMRPipe: a multidimensional spectral processing system based on UNIX pipes. J Biomol NMR. 1995, 6 (3): 277-293. 10.1007/BF00197809.PubMedGoogle Scholar
- Johnson BA, Blevins RA: Nmr View - a Computer-Program for the Visualization and Analysis of Nmr Data. J Biomol NMR. 1994, 4 (5): 603-614. 10.1007/BF00404272.View ArticlePubMedGoogle Scholar
- Slupsky CM, Boyko RF, Booth VK, Sykes BD: Smartnotebook: a semi-automated approach to protein sequential NMR resonance assignments. J Biomol NMR. 2003, 27 (4): 313-321. 10.1023/A:1025870122182.View ArticlePubMedGoogle Scholar
- Marsh JA, Singh VK, Jia Z, Forman-Kay JD: Sensitivity of secondary structure propensities to sequence differences between alpha- and gamma-synuclein: implications for fibrillation. Protein Sci. 2006, 15 (12): 2795-2804. 10.1110/ps.062465306.PubMed CentralView ArticlePubMedGoogle Scholar
- Marcotte I, Separovic F, Auger M, Gagne SM: A multidimensional 1 H NMR investigation of the conformation of methionine-enkephalin in fast-tumbling bicelles. Biophys J. 2004, 86 (3): 1587-1600. 10.1016/S0006-3495(04)74226-5.PubMed CentralView ArticlePubMedGoogle Scholar
- Nan YH, Bang JK, Shin SY: Design of novel indolicidin-derived antimicrobial peptides with enhanced cell specificity and potent anti-inflammatory activity. Peptides. 2009, 30 (5): 832-838. 10.1016/j.peptides.2009.01.015.View ArticlePubMedGoogle Scholar
- Peeters E, Nelis HJ, Coenye T: Comparison of multiple methods for quantification of microbial biofilms grown in microtiter plates. J Microbiol Methods. 2008, 72 (2): 157-165. 10.1016/j.mimet.2007.11.010.View ArticlePubMedGoogle Scholar
- Pedersen SS, Espersen F, Hoiby N, Shand GH: Purification, characterization, and immunological cross-reactivity of alginates produced by mucoid Pseudomonas aeruginosa from patients with cystic fibrosis. J Clin Microbiol. 1989, 27 (4): 691-699.PubMed CentralPubMedGoogle Scholar
- Ambrosi C, Tiburzi F, Imperi F, Putignani L, Visca P: Involvement of AlgQ in transcriptional regulation of pyoverdine genes in Pseudomonas aeruginosa PAO1. J Bacteriol. 2005, 187 (15): 5097-5107. 10.1128/JB.187.15.5097-5107.2005.PubMed CentralView ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.